First authorization to resume patient enrollment in the Phase 3 study of masitinib in ALS
The text version of this document is not available. You can access the original document here.
AB Science SA published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 August 2021 17:54:10 UTC.